- Home
- VEL vs MYGN Comparison
VEL vs MYGN Comparison
Compare VEL & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VEL
- MYGN
- Stock Information
- Founded
- VEL 2004
- MYGN 1991
- Country
- VEL United States
- MYGN United States
- Employees
- VEL N/A
- MYGN N/A
- Industry
- VEL Finance: Consumer Services
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- VEL Finance
- MYGN Health Care
- Exchange
- VEL Nasdaq
- MYGN Nasdaq
- Market Cap
- VEL 602.1M
- MYGN 642.0M
- IPO Year
- VEL 2020
- MYGN 1995
- Fundamental
- Price
- VEL $18.71
- MYGN $7.24
- Analyst Decision
- VEL Buy
- MYGN Hold
- Analyst Count
- VEL 5
- MYGN 13
- Target Price
- VEL $21.20
- MYGN $13.50
- AVG Volume (30 Days)
- VEL 105.7K
- MYGN 1.4M
- Earning Date
- VEL 11-06-2025
- MYGN 11-06-2025
- Dividend Yield
- VEL N/A
- MYGN N/A
- EPS Growth
- VEL 26.95
- MYGN N/A
- EPS
- VEL 2.22
- MYGN N/A
- Revenue
- VEL $195,592,000.00
- MYGN $832,900,000.00
- Revenue This Year
- VEL $3.99
- MYGN $0.17
- Revenue Next Year
- VEL $29.69
- MYGN $6.19
- P/E Ratio
- VEL $8.44
- MYGN N/A
- Revenue Growth
- VEL 44.29
- MYGN 3.83
- 52 Week Low
- VEL $16.12
- MYGN $3.76
- 52 Week High
- VEL $20.98
- MYGN $29.30
- Technical
- Relative Strength Index (RSI)
- VEL 51.26
- MYGN 65.47
- Support Level
- VEL $18.44
- MYGN $6.73
- Resistance Level
- VEL $19.21
- MYGN $7.05
- Average True Range (ATR)
- VEL 0.38
- MYGN 0.40
- MACD
- VEL -0.08
- MYGN 0.07
- Stochastic Oscillator
- VEL 29.35
- MYGN 72.28
About VEL Velocity Financial Inc.
Velocity Financial Inc is a United States-based real estate finance company. The company originates and manages investor loans secured by residential rental and small commercial properties. The company earns revenue in the form of interest income. It operates in New York, California, Florida, New Jersey, and other states.
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.